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ABSTRACT
Essentially all asthmatics demonstrate a marked sensi-
tivity to inhaled methacholine and histamine, termed
non-specific bronchial (airway) hyperresponsiveness
(BHR). Airway hyperresponsiveness is a characteristic
not only of asthmatics, but can be found in many
persons with allergic rhinitis as well as in members
of asthmatics' families. The presence of BHR usually
precedes the development of clinically identifiable
asthma. In recent years there has been an emphasis
on inflammation, inducing hyperresponsiveness. How-
ever, these factors increase airway hyperresponsive-
ness by a magnitude of only three-fold compared with
normal subjects. The important question is not why
asthmatics respond, but why normal subjects do not.
The normal subjects are quite able to maintain normal
airway function in the presence of high concentrations
of methacholine or histamine in vivo but not in vitro,
suggesting the presence of protective mechanisms in
vivo that are either lacking in, or are less effective
in, the asthmatic subjects. There is a strong correlation
between the degree of airway hyperresponsiveness
and the severity of asthma. In order to determine
whether methacholine sensitivity could be used as a
potential genetic marker, we studied 750 subjects from
53 asthma families and 26 control families. The best
sensitivity and specificity is at 200 breath units. Only
6% of the allergic rhinitis subjects showed a high posi-
tive response, but 30% overlapped with asthmatics in
that they reacted with 200 breath units or less. There
was a group of non-atopic subjects from asthma fami-
lies who responded by 200 breath units, but there was
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a significantly lower percentage from normal families.
Being from an asthma family is a risk factor in terms of
subsequent development of asthma and increased air-
way reactivity. The parent data suggest that airway
reactivity is transmitted to succeeding generations.
Studies of twins have revealed that the concordance of
asthma is higher in monozygotic than in dizygotic
twins, but environmental factors are at least as impor-
tant as genetic factors. Animal models of asthma
comparing genetic strains can provide an important
link between airway hyperresponsiveness and the
allergic response. The inheritance of asthma fits a
polygenetic pattern rather than a single-gene pattern.
Key words: adenylate cyclase, airway hyperresponsive-
ness, allergic rhinitis, asthma, asthmatics, bronchial
(airway) hyperresponsiveness, chromosome, cytokines,
eosinophils, families, genetic, histamine, IgE, metha-
choline, phosphodiesterase, twins.
INTRODUCTION AND HISTORICAL PERSPECTIVE
Asthma is a well-recognized and common condition.
Nearly all asthmatics demonstrate recurrent episodes of
shortness of breath, wheezing, and coughing. Asthmatics
generally respond to bronchodilator medication. All
asthmatics demonstrate a marked sensitivity to inhaled
methacholine and histamine.' termed non-specific bron-
chial (airway) hyperresponsiveness (BHR). Airway hyper-
responsiveness is a characteristic not only of asthmatics,
but can be found in many persons with allergic rhinitis 1
and members of asthmatics' Icmilies.? A recent report
suggested that the presence of BHR usually precedes the
development of clinically identifiable osthrnc.? We repor-
ted on 20 subjects who were studied before and after the
onset of clinical asthma. Subjects were part of a larger
ongoing study of the 'Natural History of Asthma'.
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The results showed that enhanced airway reactivity
usually precedes the development of asthma, which could
support the theory that asthma has a genetic basis.
Asthma is characterized by a constellation of biochem-
ical, hematological, and pharmacological abnormalities.
It is generally accepted that both genetic and environ-
mental influences playa role in its development.
Figure 1 shows the characteristics of asthma that encom-
pass its pathogenesis and need to be included in any theory
regarding asthma.
BRONCHIAL HYPERRESPONSIVENESS
Viral infections, industrial pollutants, and exposure to aller-
gens can all increase airway hyperresponsiveness and
induce inflammation. In recent years there has been an
emphasis on inflammation, inducing hyperresponsiveness.
However, these factors increase airway hyperrespon-
siveness by a magnitude of only three-fold, whereas the
hyperresponsiveness of the asthmatic is increased at least
three log, or 1OOO-fold, compared with normal subjects.
The important question is not why asthmatics respond,
but why normal subjects do not. Normal subjects have
been challenged with up to 256 mg/mL of methacholine
and have still failed to show a 20% fall in the forced
expiratory volume in 1 s (FEV]). However, if the airway is
removed and put in a muscle bath, the normal subjects
respond very effectively to histamine or methacholine at
very low concentrctlons.v" A review of literature shows
that there is essentially no difference in vitro between
normal subjects and asthmatics in terms of methacholine
or histamine sensitivity.5,6 The normal subjects are quite
able to maintain normal airway function in the presence
of high concentrations of methacholine or histamine
in vivo but not in vitro. This suggests the presence of a
protective mechanism in vivo that is either lacking in, or is
less effective in, the asthmatic subjects.
There is a strong correlation between the degree of
airway hyperresponsiveness and the severity of asthma/,8
the more severe the asthma, the greater the airway hyper-
responsiveness. The slope of the dose-response curve is
steeper and the degree of response greater, with the
maximum fall being obviously larger, in patients with
severe asthma than in those with milder asthma (Fig. 2).
A plateau phenomenon is commonly seen in allergic
rhinitis subjects as well as in many former asthmatics and
indeed in current asthmatics following a therapeutic course
of inhaled corticosteroids. Former asthmatics as a group
are about one-tenth as sensitive as current osthmotics.?
This plateau phenomenon which may occur at different
degrees of fall in FEV] and subsequent increasing concen-
trations of methacholine, does not result in a further
decrease in the FEV1• Subjects with current symptomatic
asthma do not generally reach ploteou.? In asthmatic sub-
jects, a significant direct correlation between airway
sensitivity to methacholine or histamine and peak expira-
tory flow variability has been shown, but the relationship
Bronchial
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Fig. 1 These characteristics encompass the pathogenesis of
asthma and need to be included in any theory regarding it.
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Fig. 2 Typical dose-response curves to methacholine in sub-
jects with moderate (0) and mild (e) asthma, in subjects with
past asthma (no wheezing for at least 12 months) or allergic
rhinitis (--), and in normal subjects (.).
between peak expiratory flow variation and maximal
response plateau to pharmacologic agents has not been
investigated.10,11
Recently, Cloosterman et 0/. reported on the relation-
ship between the variability of peak expiratory flow rate in
allergic rhinitis and mild asthma. These authors also
reported on the variation among subjects with plateau
response curves to methacholine and subjects without
ploteou.'? They concluded that in both asthmatic patients
and subjects with allergic rhinitis, the shape of the
concentration-response curve to methacholine provided
new information on the relationship between airway
responsiveness and peak expiratory variability. Clooster-
man et at. also concluded that some subjects with allergic
rhinitis without evidence of plateau had degrees of diur-
nal peak expiratory flow variation similar to that found in
patients with mild asthma. This could indicate that those
subjects had subclinical inflammatory changes in the
airways. It should be emphasized that most of the allergic
rhinitis subjects develop a plateau at much lower falls in
FEV1 compared with asthmatic subjects. A maximal res-
ponse plateau is a feature of normal persons and also
of many subjects with allergic rhinitis. 13- 15 In contrast,
in patients with current symptomatic asthma increasing
doses of inhaled pharmacologic agents usually led to
progressive airway narrowing without the achievement of
a ploteou.Y!"
Subjects with mild asthma had a lower prevalence
(22%) of plateau on the concentration-response curves
to methacholine than did subjects with allergic rhinitis
(63%) or healthy subjects (94%). With regard to subjects
for whom plateau was detected, the level of maximal
response was significantly higher in subjects with asthma.
These observations show that non-asthmatic subjects with
allergic rhinitis without evidence of plateau have a
degree of daily peak expiratory flow variation greater
than do healthy subjects and similar to that found in
patients with mild asthma. These individuals may be at
greater risk of developing clinical asthma. These findings
are consistent with the observations of Ryan,ll who found
that an increase in diurnal expiratory flow variation in
some non-asthmatic subjects with allergic rhinitis was
associated with increased histamine sensitivity.
On the basis of the above studies, it is reasonable to
speculate that subjects with allergic rhinitis without evi-
dence of plateau could be at increased risk of developing
asthma, particularly if they also show increased expiratory
variation and if they are exposed to sufficiently strong
stimuli. Further prospective studies are needed to inves-
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tigate this hypothesis. In this regard, Cloosterman et 0/.
reported that house dust mite avoidance may improve
peak flow and symptoms in patients with allergy but
without asthma. They concluded that this results in a
possible delay in the manifestation of clinical asthma. 12
These authors reported significant improvements in the
treatment group in terms of symptom scores for disturbed
sleep, wheeze and breathlessness following house dust
mite avoidance compared with the placebo group. Lar-
ger studies with a long follow-up period are necessary to
indicate protection against clinically manifest asthma in
these subjects with house dust mite allergy.
Genetic studies using measurement of airway
hyperresponsiveness
Family studies
In order to determine whether methacholine sensitivity
could be used as a potential genetic marker, we studied
750 subjects from 53 asthma families and 26 control
families. 13, 14 The asthma families were defined as having
a proband with current bronchial asthma between the
age of 6 and 25 years. Both parents had to participate in
the testing.
The control families were usually neighbors of the
asthma families, were of the same age group and had no
atopic disease.
We measured the area under the dose-response curve
using the best-fit parabolic corve." Subjects who had a
highly positive response were very sensitive to metha-
choline and had a small area under the parabolic-
response curve. We used a 35% fall in FEV1 as an end
point to take into consideration the plateau phenome-
non. This allowed us to separate subjects who had a 20%
fall in FEV1 and then plateaued, from current asthmatics
who, for the most part, did not show a plateau pheno-
menon. A negative study was defined as one having less
than a 20%fall in FEV1after 800 cumulative breath units
of methacholine.
Table 1. Characterization of methacholine inhalation response
Category % Drop in Cumulative Area under
FEV1 dose the curve
----------
High ~ 20% 0-5 0-306
Medium ~ 20% 51-200 306-1225
Low ~ 20% 201-800 1225-4000
Negative < 20% > 800 4000-5600
FEYl = forced expired volume in 1 second.
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Fig. 3 Frequency plot of age-correlated area under dose-
response curves for methacholine in normal subjects from both
asthmatic (e) and control (0) families. Left-hand mode shows
excess number of positive responders from asthmatic families.
normal children from the normal families demonstrated a
unimodal distribution. The results clearly show a bimodal
distribution of the parents of the asthma families.
There was no difference in sex distribution, age or
serum IgE when we compared these groups, but again
there was a slight but significant difference in total skin
test score.!" The parents of asthmatics who did respond
to methacholine had a somewhat greater total intra-
dermal skin test score.
This bimodal distribution of airway reactivity in the non-
atopic siblings of asthmatics and in non-atopic parents of
asthmatic children would suggest a single physiological,
or perhaps a single genetic, abnormality. Consistent with
these results is the report by Longo et 01., who also found
bimodal distribution of airway reactivity in parents of asth-
matic children but not in control porents.F? In our study,
however, a simple genetic effect was not evident because
segregation analysis of these families excluded a single-
gene mechanism. 14,2o
Clifford et 01. studied 50 children who had one parent
with osthrnc.P These children had a 50% increase in res-
piratory symptoms of cough, wheeze and shortness of
breath when compared with control subjects. Over 90%
of the asthmatic parents responded to methacholine with
a 20% fall in FEV1 by 6.4 umol,while 45% of the children
had similar responses.
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Table 1 compares area and cumulative dose in breath
units. A subject who had a 20% fall in FEVl , with 50
breath units or less, would have had a maximum area of
306, whereas a subject with a medium response, with a
20% fall in FEV1 at 200 breath units or less, would have
had an area of up to 1225. The standard diagnostic
method goes up to only 200 cumulative breath units. 16, 17
Most children with asthma in our family study respon-
ded to 50 breath units or less. The few non-responders
were former asthmatics who, by definition, had been free
of all symptoms for at least 1 year. The majority of the
normal children from the normal families failed to react,
even at 800 breath units. If we analyze the pediatric pop-
ulation from these families, the best sensitivity and
specificity was found at about 100 breath units.!"
However, when the total population is analyzed, the best
sensitivity and specificity is at 200 breath units. 1S This
illustrates that normal children have a greater bronchial
reactivity than do adults. 16 , 17, 19
Data for the whole population studied showed that
the asthmatics, for the most part, reacted by 50 breath
units or less, but that some asthmatics did not react
until 200 breath units.l ' Only 6% of the allergic rhinitis
subjects showed a high positive response, but 30%
overlapped with asthmatics in that they reacted with
200 breath units or less. There was a group of non-
atopic subjects from asthma families who responded by
200 breath units, but there was a significantly lower
percentage from normal Iornilies."
Results for the normal non-atopic subjects from the
asthma families versus the normal subjects from the
non-atopic families are shown in Fig. 3. This shows a
subgroup of subjects from asthma families who respond
to methacholine and who are siblings of asthmatics. 1s,2o
These responders are perhaps at greater risk for sub-
sequent development of asthma. The normal subjects
from normal families show a unimodal distribution. How-
ever, the normal subjects from the asthma families clearly
show a bimodal response. When we compared the
characteristics of the responders and the non-responders,
there was no difference in the sex distribution, mean age,
or serum IgE. There was a slight difference in the total
intradermal skin test score, and although this was statis-
tically significant, these scores are small compared with
the scores of subjects with known atopic disease.
Data for the parents of normal children from the non-
atopic families and the parents of the children with asthma
have been reported. 18,21 All asthmatic subjects were elimi-
nated for the purpose of comparison. The parents of the
We performed a segregation analysis on the bronchial
response to a standardized methacholine inhalation chal-
lenge obtained from members of 83 families that were part
of a Natural History of Asthma study population. Each
bronchial response was expressed as the area under
the best fitting parabolic dose-response curve. Standard
methods of statistical analysis demonstrated that age, sex,
and recent respiratory infection had a significant effect
on the bronchial response to methacholine inhalation.
Segregation analysis indicated that, although a familial
component exists in the transmission of bronchial response
to methacholine, the bimodal distribution of the bronchial
response is not due to segregation at a single autosomal
locus." Airway reactivity appears to be determined by both
genetic and environmental factors. It is our conclusion that
its inheritance is due to a polygenetic mechanism. There
may be more than one major locus: polygenic inheritance,
culturally transmitted environmental effect, or perhaps a
mixture of these mechanisms.
Methacholine and histamine challenges are the most
sensitive indicators of non-specific bronchial reactivity.
Other tests such as exercise and osmotic challenges have
been used to determine the degree of bronchial sensi-
tivity in asthmatics and allergic rhinitis subjects. Exercise
challenges have been used to determine the degree of
bronchial lability in relatives of asthmatics. Konig and
Godfrey reported exercise challenge and skin test results in
65 first degree relatives of 12 children with csthrno.?" Posi-
tive index for enhanced bronchial lability was obtained
in 10 of the 12 asthmatic children. Overall, 28 of the 65
family members responded. It is impressive that many non-
asthmatic subjects responded to a challenge that generally
is not considered to be as sensitive as methacholine.
The use of non-isotonic aerosols for evaluating bronchial
hyperresponsivenesshas been studied extensivelyby Ander-
son et 0/. 25 Challenges with non-isotonic aerosols, that is
osmotic challenges, including those using hypertonic saline
(4.5%), require little patient cooperation and the equipment
required is portable, relatively inexpensive, and readily
available. Bronchial challenge by inhaling hyperosmolar
saline has the advantage of being a physiologic challenge
rather than a pharmacologic one. It can also be used in
children. These osmotic challenges cause bronchoconstric-
tion indirectly by causing the endogenous release of
mediators to which the subject is sensitive. Although these
osmotic challenges are lesssensitive in detecting bronchial
hyperreactivity than challenges with methacholine and his-
tamine, they have a high positive predictive value for
identifying bronchial hyperreactivity associated with moder-
METHACHOLINE HYPERSENSITIVITY STUDIES 767
ate to severe asthma. 26,27 Anderson et 0/. reported no false-
positive tests in osmotic challenges in healthy subjects."
This is in contrast to histamine and methacholine challenges
which, as mentioned, have relatively low specificity but a
high negative predictive value. In the population studies
and family studies discussed, approximately 30% of persons
with hyperresponsiveness to methacholine and histamine
have no symptoms of asthma.
The Bronchoprovocation Committee of the American
Academy of Allergy, Asthma and Immunology has con-
ducted a multicenter study of the effect of hypertonic
saline challenges in asthmatics, allergic rhinitis subjects
and control non-atopic subjects. In this study of 80 sub-
jects, all asthmatics responded to methacholine whereas
only 75% responded to hypertonic saline with a 20% fall
in FEV1 • Two of the 20 subjects with allergic rhinitis had a
positive response to methacholine and these subjects
also responded to hypertonic saline. No normal subject
responded to methacholine or hypertonic saline. Overall,
it can be said that the osmotic challenges are more spe-
cific but less sensitive than the direct pharmacologic
challenges using histamine and methacholine. Anderson
et 0/. have compared the airway responses to metha-
choline and histamine with 4.5% saline in 26 subjects."
The results demonstrate that a PD20 to 4.5% saline of
less than 15 mL is associated with a PD20 to histamine of
less than 2 umol (PC20 of 4 mg/mL). A PD20 for metha-
choline was also less than 2 umol. In patients with a
PD20 to 4.5% saline less than 15 mL, the authors always
observed responsiveness to methacholine or histamine.
Twin studies
Although there are limitations in using the twin model to
examine the influence of heredity, genetic analysis of twins
remains an accessible and practical method of estimating
the weight of genetic influence on clinically measurable
parameters. This is true because members of a monozy-
gous pair share a genotype and a relatively similar
environment. By comparing clinical or laboratory para-
meters of a disease condition in monozygous (MZ) twins
and dizygous (DZ) twins, it is possible to provide evidence
for the genetic determination of those parameters, under
reasonable ossurnptions."
The comparison of intrapair correlation coefficients (r)
provides an indicator of the role of heredity as a clinical
marker of atopic disease or bronchial hyperresponsive-
ness. An estimate of heritability ((H)2, rMZ-rDZ) has been
used .28 This heritability index provides an estimation of the
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Fig. 4 (a) Intrapair correlation of methacholine (metholyl) sensitivity as determined by the area under the dose-response
curve. Methacholine area expressed as the natural log shows a correlation coefficient of 0.67 in monozygous (MZ) twins
(0; r = 0.67) and 0.34 in dizygous (DZ) twins (e; r = 0.34).
contribution of heredity to the variants of the measured
trait or marker. When H = 1, the variance of the mea-
surement is entirely due to heredity. As H approaches 0,
the variance of the measurement is presumed to be deter-
mined by environmental factors. Pair and casewise
(proband) concordance rates of a trait are also com-
monly used to express the results of twin data.
A standardized exercise challenge test has been used
to compare eight identical and seven-non-identical twin
poirs.F? These authors found that six pairs of MZ twins
were concordant for exercise lability, while only one of the
DZ pairs was concordant.
In our twin studies (Fig. 4a,b), the correlation of metha-
choline area in 61 pairs of MZ and 47 pairs of DZ twins
was determined.
We observed a significantly greater correlation coeffi-
cient of methacholine sensitivity in the MZ twins (0.67)
than in the DZ twins (0.34).30
We also compared serum IgE levels in the MZ and DZ
twins and found a higher correlation coefficient in the MZ
twins. The heritability estimate for the IgE was 0.61, and
for the methacholine sensitivity it was 0.66.30
Insight into the genetic contribution to pulmonary func-
tion as reflected in twin studies was reported by Ackerman
et 01., who investigated 39 twin pairs at a mean age of 11.4
rnonths.?' This study included 25 MZ and 14 DZ pairs.
Thirty per cent of the twin pairs had a positive family history
of asthma. Pulmonary function in the infants was deter-
mined in a sleep state and the measurement of maximal
expiratory functional residual capacity was performed with
rapid chest compression. A greater intrapair variation in
pulmonary measurements was observed between DZ twins
than between MZ twins. Similar findings had previously
been reported for a large population of adult twins in a
study using standard pulmonary function testing.32
We concluded that methacholine can determine the
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degree of bronchial reactivity, which is certainly a hallmark
of asthma. Just coming from an asthma family is a risk
factor in terms of subsequent development of asthma and
increased airway reactivity. The parent data suggest that
airway reactivity is transmitted to succeeding generations.
Studies of twins have revealed that the concordance of
asthma airway reactivity and IgE is higher in monozygotic
than in dizygotic twins, but that environmental factors are
at least as important as genetic factors. Animal models of
asthma comparing genetic strains can provide an impor-
tant link between airway hyperresponsiveness and the
allergic response. The inheritance of asthma fits a poly-
genetic pattern rather than a single-gene pattern.
Effect of age on bronchial hyperresponsiveness
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We have investigated the effect of age on methacholine
sensitivity in a population study of over 750 subjects.'?
When methacholine responsiveness is plotted against
age (Fig. 5) for subjects who have no history of asthma,
Fig. 5 Methacholine responses of subjects studied. Results z
4000 indicate normal responses. Values ~ 1535 indicate
values that are ~ 200 breath units of methacholine. The best-
fitting curve is superimposed. r = 0.42; P < 0.00001.
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Studies in animals: Dogs, guinea pigs and mice
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Fig. 6 Bronchial sensitivity to serotonin, histamine, and metha-
choline in ~-adrenergically blocked guinea pigs. (_), Hartley; (BllI),
Trapani-Campbell; C, control; BB, Beta Blockade. *P < 0.01.
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Animal models of asthma have demonstrated increased
non-specific bronchial responsiveness. Basenji-greyhound
(BG) crosses have proved a valuable animal model. Each
breed (i.e. Basenji and greyhound) has minimal or no BHR
inherently, but the BG dog does have inherent BHR.36 The
Basenji dog and the BG dog often have atopic dermatitis,
although non-atopic BG dogs can have BHR.
Thirty years ago we reported that sensitization to
anaphylaxis and some of its pharmacologic mediators
could be induced by a blockade of the beta adrenergic
receptors in certain specific strains of mice and guinea
pigs. In Hartley strain guinea pigs time of onset of severe
dyspnea (Fig. 6) after inhalation of serotonin, histamine
or methacholine was significantly decreased when the
strain was pretreated with a beta adrenergic blocking
agent. This is not unlike the effect of beta adrenergic
blocking agents seen in csthrnctics.:" In contrast, the beta
adrenergic blocking agent did not induce significant
increased reactivity to serotonin, histamine or to metha-
choline in the Trapani-Campbell strain .38
and frequency of development of asthma symptoms
than did normoresponsive subjects. Allergen exposure
in sensitized subjects at the time of the study, and
genetic predisposition, seemed the main risk factors
for the development of symptomatic asthma in this
popu lation. 35
it can be very easily appreciated that the younger and
older subjects have significantly increased bronchial
responsiveness. If this factor is not taken into account in
clinical practice, there could be a tendency to suggest
falsely the presence of hyperresponsive airways in these
populations.
Allergic non-asthmatic children have increased non-
specific bronchial responsiveness and this increased
bronchial responsiveness persists over time. 33 We have
postulated that persons with allergies and family members
of asthmatic subjects retain this enhanced bronchial
responsiveness, thus increasing their likelihood of subse-
quently developing asthma. These findings, along with
others, would require that increased bronchial responsive-
ness precede the development of asthma symptoms. In
our asthma family population we evaluated bronchial
reactivity over several years and were able to show that
17 of 20 children who years later developed asthma had
pre-existing bronchial recctivitv' Increased airway respon-
siveness pre-existing in children who later became clinically
asthmatic has also been reported by Sears et 01. 34 These
studies suggest, but do not prove, that airway hyper-
responsiveness may be genetically determined.
The natural history and significance of asympto-
matic airway hyperresponsiveness (AHR) are still to be
defined. Over a 3 year period, Laprise and Boulet
compared clinical, immunologic, and physiologic
features of 30 subjects who had asymptomatic AHR
with those of 30 symptomatic asthmatic subjects and
30 normal non-responder subjects (age, 31.9 ± 1.4
yea rs; mea n ± SEM; n = 90).35 These tests were
repeated annually, at the same period of the year, for
3 years. Subjects with asymptomatic AHR had greater
bronchodilator responses (P = 0.001), variability of
peak expiratory flow rate (P = 0.002), and prevalence
of atopy (P = 0.02) than did the normoreactive sub-
jects. After 3 years, the concentration of methacholine
provoking a 20% decrease in FEV1 (PC20) had
decreased significantly in the asymptomatic AHR sub-
jects (P < 0.0001) as compared with the other two
groups, and of the 28 subjects studied at this time,
four (14.3%) had developed asthma symptoms. These
last four subjects were atopic and had been exposed
to animals when they developed asthma. They also
had a familial history of asthma and an increased
baseline AHR compared with the subjects who did not
develop symptoms. In conclusion, this study showed
that over a 3 year period, subjects with asymptomatic
AHR had a greater increase in airway responsiveness
More recently, studies using mice have shown that spe-
cific strains have an increased response whereas others
are totally unresponsive. Breeding between strains has
shown a genetic susceptibility to bronchial hyperreactivity
in mice that is not associated with atopy.38,39 A marked
strain difference in sensitivity to serotonin and metha-
choline exists in mice. 38,40,41
We investigated the sensitivity of different mouse strains
to histamine and methacholine. Pertussis toxin or low
dose of the beta adrenergic blocking agent sotalol fol-
lowed by histamine challenge resulted in the death of all
CFW strain mice. 38,41 In CF1 mice, however, the same
low dose of beta blocker was not lethal and this strain
was also resistant to the sensitizing effect of pertussis
toxin. However, in the CF 1 mice, this resistance to his-
tamine was overcome when a higher dose of beta
adrenergic blocker was used and resulted in a mortality
rate of 80%. The obese hyperglycemic mouse, a genetic
strain that has been used to study Type II diabetes, is resis-
tant to sensitivity to histamine induced even by high doses
of beta adrenergic blocking agents. However, the normal
litter mates of these obese hyperglycemic mice are sensi-
tive to histamine following a high dose of beta adrenergic
blocker. Because of the recent advances in measuring
airway sensitivity in awake, unanesthetized mice, the fact
that pure inbred strains of mice are readily available and
that environmental factors can be easily controlled and
manipulated, it is now possible to design experiments
to study the various components involved in the patho-
genesis of asthma in this mouse model (Fig. 1). Animal
models and human studies support the hypothesis of
genetic control of bronchial hyperreactivity. Intense efforts
to relate this bronchial hyperreactivity by linkage analysis
are currently under way in a number of laboratories
around the world.
GENETICS OF IMMUNOGLOBULIN E, T CELLS
AND CYTOKINES
The presence of atopic diseases, such as allergic rhinitis,
has a strong genetic deterrninction.F'P The ability to
generate IgE response to a specific antigen has been
conclusively shown to be associated with specific histo-
compatibility antigen loci. 43 Cookson et a/. have recently
analyzed maternally derived alleles from 155 sibling
pairs affected by atopy to markers on chromosome
11q 13. 44 They found that the ~ subunit was a candidate
for the chromosome 11 atopy locus. These investigators
also found that paternal transmission of atopy does not
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occur at the chromosome 11q 13 locus. At present, the
exact localization of gene(s) for the predilection to be
atopic (lgE) is in question. The original observations
linking atopy with chromosomes 11 and 5 need further
investigation. An intensive effort to identify the genes as-
sociated with asthma and airway hyperresponsiveness is
currently in progress in Europe, North America and Asia.
Mouse strains have been shown to have a T-helper popu-
lation (Th2) preferentially producing cytokines (IL-4 and
IL-5) that induce a response to porcsites." Several labora-
tories have recently reported an induction of airway
hyperresponsiveness, increased IgE and eosinophilia in a
mouse model of asthma after ovalbumin inhalation in sen-
sitized mice.46,47 In sensitized animals, repeated inhalation
of ovalbumin induces airway hyperresponsiveness in vivo,
infiltration of eosinophils and CD4+ cells in lavage and
airway tissue with Th2-type cytokines IL-4 and IL-5. The role
of IL-16 in upregulation of IgE, eosinophil infiltration and
airway hyperresponsiveness has been demonstrated by
these outhors.f This response was significantly inhibited
after the addition of antibodies to IL-16, a T lymphocyte
chemo-attractant factor that utilizes CD4 molecules as its
receptor. Interleukin-16 is more potent than platelet activat-
ing factor as an eosinophil chemo-attractant. As reviewed
by Hesselet a/.,47 IL-16 may play an important role in airway
inflammation in allergic asthma. The recent finding that
IL-16 is present in bronchial lavage fluid of allergic asthmat-
ics 6 h after allergen bronchial provocation, but not in
allergen challenged normal subjects or allergen challenged
allergic rhinitis subjects, supports this hypothesis. Further-
more, airway epithelial cells of asthmatics, but not normals
or atopic non-asthmatics, contain both IL-16 nRNA and
protein. Given that histamine has been reported to induce
release of IL-16 and because it is a potent chemo-attractant
for CD4 + cells and eosinophils and induces airway hyper-
responsiveness, it is reasonable to speculate that IL-16
provides a link between the early and late allergen res-
ponse. Furthermore, IL-16 could be an important factor
in target organ specificity because it is a CD4 + chemo-
attractant and is present in the bronchial lavage of allergic
asthmatics but not in allergic non-asthmatics after allergen
challenge. Could IL-16 acting by the above mechanism
determine why some atopic individuals have bronchial
asthma whereas other subjects who are equally sensitive to
an allergen develop allergic rhinitis?
A study in human atopic asthmatics showed significant
increases in Th2-like broncho-alveolar lavage fluid cyto-
kines, in comparison with normal subjects including IL-4,
IL-5, and granulocyte-macrophage colony-stimulating
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foetor." The presence of specific phenotypically different
human C04 + T cells has not been clearly established to
date, although T cell clones from mite-sensitive subjects
produce IL-4 and IL-5 on exposure to mite ollerqen."" In
humans, the genetic drive to produce a Th2-like cytokine
pool (IL-4, IL-5, IL-10 and IL-13) in response to allergen
exposure is highly probable.
In atopic subjects there is an increased percentage of
monocytes and macrophages that have surface IgE recep-
tor positivity. Macrophages reside at the critical air-surface
interface, and the presence of IgE on macrophage surfaces
may be critical in asthma. Macrophages have the ability to
release LTB4 and platelet activating factor, both eosinophil
chemo-attractants. Interferon-y alters macrophage func-
tion. This Iymphokine, as well as IL-4, may regulate IgE
receptor density on lung mocrophcqes"
ADRENERGIC RECEPTOR DYSFUNCTION AND
PHOSPHODIESTERASE
Recent studies using bronchial alveolar macrophages
have shown that both salbutamol (homologous) and
prostaglandin E (heterologous) stimulation of cAMP
production in asthmatics is deficient, suggesting a non-
~2-receptor defect." Since ~-receptor hyporesponsive-
ness is probably not directly caused by intrinsic defect(s)
in the ~-receptor itself, it would suggest potential
defects in the signal transduction pathway involving
guanine nucleotide regulatory protein, adenylate cyclase
enzyme, or even phosphodiesterase (POE). The Basenji-
greyhound dog model demonstrates a role for POE
levels in the pathogenesis of the atopic phenotype of
this animal. 52 Phosphodiesterase levels and bronchial
responsiveness to methacholine are increased in the
cross-breed, intermediate in the Basenji, and low in the
greyhound. Increased POE activity has been demon-
strated in atopic dermatitis and allergic rhinitis subjects.P
Phosphodiesterase inhibitors are under clinical inves-
tigation in csthrnc." Five isoenzyme types of POE are
recognized, with POE4 having the highest affinity for
cAMP. Studies of POE4 levels in basal U-937 cells showed
that exogenous ~-agonists increased POE4 levels in a
time- and dose-dependent manner. 55 This suggests an
important functional link between ~-agonists and the
POE4 level. The five isoenzymes are coded by distinct but
probably related genes. The genetic profile for POE in
asthmatics or allergic subjects is yet unknown.
Phosphodiesterase-4 inhibitors have modulatory effects
on peripheral blood mononuclear cell (PBMC) cytokine
secretion. Reports of their effect on production of the
immunosuppressive cytokine IL-10 differ, but there is
overall agreement that they inhibit tumor necrosis factor
(TNF)-a secretion. The effect of two POE4 inhibitors on
IL-10 and TNF-a production by PBMC from non-atopic
versus atopic individuals has been compcred.P" The POE4
inhibitors caused a concentration-dependent inhibition in
the secretion of both TNF-a and IL-10. These drugs were
more potent in suppressing cytokine secretion by PBMC
from atopic than from non-atopic donors. They were also
more potent in preventing TNF-a than IL-10 secretion.
Since the POE4 inhibitors are selectively more potent in
inhibiting TNF-a secretion by cells from atopic than from
non-atopic donors, but not as effective in the suppression
of IL-10, they may have a potentially important role in the
treatment of allergic disease.
ENVIRONMENTAL FACTORS
Two factors commonly associated with the onset of
asthma include viral illness and exposure to tobacco
smoke. Bronchial asthma, which is always debilitating
and occasionally fatal, is one of the most common
chronic diseases in the world. In the USA, asthma is the
number one chronic disease causing school absences
and its prevalence in industrialized nations has doubled
in the last 20 years. Furthermore, in spite of recent
advances in treatment and in the prescribing of therapy,
deaths from asthma have continued to rise to epidemic
levels. Although the reason for the onset of this asthma
epidemic is unknown, the localization of the problem to
industrialized nations suggests causative agents such as
poorly ventilated, allergen-friendly modern homes, air
pollution, smoking or, as we suspect, the decline in inci-
dence of childhood infections.
It is now recognized that allergies are the result of an
imbalance in the immune system (Fig. 7). This skews the
inflammatory response to common, harmless antigens so
that high levels of IgE are made and eosinophils are acti-
vated. Childhood infections frequently cause the other
arm of the immune system to be activated, so that IgG is
formed and there is a non-allergic immune or delayed
type of hypersensitivity response, as exemplified by the
tuberculin skin test reaction. Studies have revealed that
these two arms of the immune system provide a system of
checks and balances for each other. For example, IL-4,
one of the immune proteins secreted by cells (Th2)
involved in allergy, prevents delayed type hypersensitivity
reactions. In comparison, the immune proteins IL-12 and
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Fig. 7 Immune balance.
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interferon-y, which are secreted by cells (Th1) involved in
delayed type hypersensitivity, inhibit the Th2 cells, which
mediate allergic responses. Because the main risk factor
for the development of asthma is allergy, it is logical that
a decrease in childhood infections may increase the inci-
dence of allergy by allowing the immune balance to shift
to the right (Fig. 7). Indeed, the literature provides some
evidence that this is the case.57,58 Conversely, we predict
that if one can drive the immune balance towards the
delayed type hypersensitivity reaction (left), allergy symp-
toms will decline.
CONCLUSION
The findings of this study were as follows:
1. Methacholine can determine the degree of bron-
chial reactivity, which is certainly a hallmark of asthma.
2. Being from an asthma family is a risk factor in terms
of the subsequent development of asthma and increased
airway reactivity.
3. The parent data suggest that airway reactivity is
transmitted to succeeding generations.
4. Studies of twins have revealed that the concordance
of asthma is higher in monozygotic than in dizygotic twins,
but that environmental factors are at least as important as
genetic factors.
5. Animal models of asthma comparing genetic strains
can provide an important link between airway hyper-
responsiveness and the allergic response.
6. The inheritance of asthma fits a polygenetic pattern
rather than a single-gene pattern.
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